New York, May 21, 2026, 08:07 EDT
- Liminatus Pharma agreed to buy InnocsAI in an all-stock deal, meaning it would pay with shares rather than cash.
- The deal would issue 1.6 billion shares at $0.20 each, far above Liminatus’ listed 44.88 million shares outstanding.
- LIMN was quoted at $0.2844 before the regular open, up 51.4% from Wednesday’s close.
Liminatus Pharma shares jumped before the bell on Thursday after the small cancer-drug developer disclosed a deal to acquire InnocsAI LLC, a privately held oncology platform, in a transaction that would massively expand its share count.
LIMN was quoted at $0.2844 in premarket trading at 8:04 a.m. EDT, up 51.4% from its Wednesday close of $0.1878, according to StockAnalysis. Premarket trading is the session before the regular Nasdaq open.
The move matters because the acquisition would give Liminatus a broader CAR-T portfolio at a time when investors have been looking for catalysts in thinly traded biotech names. CAR-T, short for chimeric antigen receptor T-cell therapy, is a cancer treatment approach that engineers a patient’s immune cells to attack cancer.
Liminatus said in a May 20 filing that InnocsAI holders would receive 1.6 billion Liminatus common shares at $0.20 per share, plus contingent value rights, or potential future payments tied to asset sales, licenses or other exits. The filing also said Valetudo Therapeutics LLC is an InnocsAI member and that Chris Kim, Liminatus’ chief executive and a director, controls Valetudo.
The size of the stock payment is the market’s first issue. Google Finance listed 44.88 million Liminatus shares outstanding and a market value of $8.43 million, putting the proposed issuance at more than 35 times the existing share count before giving effect to warrants or other securities.
The assets to be acquired include IBC101, a CD19xCD22 CAR-T candidate for relapsed or refractory B-cell malignancies, and INC101, a preclinical solid-tumor CAR-T program. Liminatus said IBC101 had authorization from South Korea’s Ministry of Food and Drug Safety for a Phase 1/2a study in relapsed or refractory diffuse large B-cell lymphoma.
The deal would push Liminatus into a field already led by much larger players. Gilead’s Kite unit markets Yescarta for large B-cell lymphoma, while Bristol Myers Squibb’s Breyanzi is approved for several lymphoma indications, showing the clinical and manufacturing bar that smaller entrants face.
Liminatus is still financially stretched. In its March-quarter report, the company said it had $1.91 million in cash, a $1.12 million net loss for the quarter and an accumulated deficit of nearly $40.0 million as of March 31. It also warned of “substantial doubt” about its ability to continue as a going concern, an accounting phrase meaning it may need more funding to keep operating. SEC
But the rally could break the other way. The InnocsAI transaction needs approvals, the share issuance would be highly dilutive to existing holders, Liminatus has disclosed Nasdaq compliance risk, and the company may still need fresh capital; if any of those issues worsens, Thursday’s premarket bid could fade fast.
The next filings will matter more than the first price move. Liminatus said it plans to file a registration statement and proxy statement/prospectus for stockholder approval, giving investors their next look at InnocsAI’s finances, ownership and the mechanics of a deal that, for now, has turned a sub-20-cent biotech into one of the morning’s more heavily watched micro-cap trades.
